Otezla, one of the big potential blockbuster drugs Celgene (NASDAQ:CELG) is depending on to expand its revenue generation beyond Revlimid, failed a phase 3 trial in ankylosing spondylitis. And yet, at the end of the first full market day after announcing the bad news, Celgene shares were up anyway.
In the video below, health care analysts Michael Douglass and David Williamson explain why the news may not have been that bad, and why the trial wasn't fundamental to the Otezla (or Celgene) investing thesis
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson has no position in any stocks mentioned. Michael Douglass owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.